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It is uncertain whether small vessel disease underlies the relationship between Type 2 Diabetes Mellitus (T2DM) and brain atrophy.
We aimed to study whether retinal vascular architecture, as a proxy for cerebral small vessel disease, may modify or mediate
the associations of T2DM with brain volumes. In this cross-sectional study using Magnetic Resonance Imaging (MRI) scans and
retinal photographs in 451 people with and without T2DM, we measured brain volumes, geometric measures of retinal vascular
architecture, clinical retinopathy, andMRI cerebrovascular lesions.Therewere 270 peoplewith (mean age 67.3 years) and 181without
T2DM (mean age 72.9 years). T2DMwas associated with lower gray matter volume (𝑝 = 0.008). T2DMwas associated with greater
arteriolar diameter (𝑝 = 0.03) and optimality ratio (𝑝 = 0.04), but these associations were attenuated by adjustments for age and
sex. Only optimality ratio was associated with lower gray matter volume (𝑝 = 0.03).The inclusion of retinal measures in regression
models did not attenuate the association of T2DM with gray matter volume. The association of T2DM with lower gray matter
volume was independent of retinal vascular architecture and clinical retinopathy. Retinal vascular measures or retinopathy may
not be sufficiently sensitive to confirm a microvascular basis for T2DM-related brain atrophy.
1. Introduction
T2DMincreases the risk of cognitive impairment anddemen-
tia [1]. Brain atrophy mediates a substantial portion of the
association between T2DM and cognitive dysfunction [2].
Cerebrovascular disease, particularly disease of small cerebral
vessels, has been postulated as a potential pathway leading to
T2DM-related brain atrophy, possibly via inflammation and
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oxidative stress, advanced glycation, ischaemia, or infarcts [3,
4], but this is yet to be clarified. AlthoughT2DM is commonly
associated with microvascular disease [5], the associations
between T2DM and brain MRI markers of small cerebral
vessel disease such as white matter hyperintensities (WMH)
or cerebral microbleeds are not strong, with contradictory
findings in the literature [6]. The similar embryological,
anatomical, and functional properties of retinal and cerebral
vessels combined with ease of visualization of retinal vessels
make them a potentially useful surrogate of cerebral small
vessel disease [7, 8]. This has led to recent investigators using
retinal vascular imaging measures in studies of people with
and without cerebrovascular disease [7, 9–11], demonstrating
their association with the risk of future stroke [12] and
dementia [13–17]. T2DM is associated with features of clinical
retinopathy [18] and changes in vessel architecture including
greater retinal arteriolar diameter [19] and greater arteriolar
tortuosity [20]. Therefore, it is possible that retinal vascular
measures may assist in establishing a small vessel basis for
T2DM-related brain atrophy.
To explore this issue further, we aimed to use retinal
imaging to examine the roles of retinal vessel abnormali-
ties and clinical retinopathy in explaining the association
between T2DM and gray matter volume. We hypothesized
that T2DM would be associated with measures of retinal
vascular architecture and clinical retinopathy and that these
measures would mediate or modify the association between
T2DM and brain volume.
2. Materials and Methods
2.1. Sampling. We used a cross-sectional design. Our sam-
pling methods have been described previously [2]. In brief,
we recruited participants with T2DM and aged ≥55 years
who were living in specific postcodes (7000–7199) of South-
ern Tasmania into the Cognition and Diabetes in Older
Tasmanians (CDOT) study between January 2008 and Jan-
uary 2010. The National Diabetes Service Scheme (NDSS)
was used as a sampling frame. The NDSS is adminis-
tered by Diabetes Australia, providing products, informa-
tion, and support to patients with T2DM who voluntarily
enrol. The diagnosis of T2DM in the NDSS is based on
physician assessment using standard criteria (fasting plasma
glucose ≥7.0mmol/L (126mg/dL), random plasma glucose
≥11.1mmol/L (199.8mg/dL), or 2-hour glucose ≥11.1mmol/L
postoral glucose tolerance test), with registrants indicating
willingness to participate in research. Exclusion criteria were
people living in a nursing home signifying severe frailty,
those with insufficient English for cognitive testing, con-
traindication toMagnetic Resonance Imaging (MRI), or pres-
ence of cataracts (to enable successful retinal imaging). We
derived our comparison group from a sample of people aged
≥60 years without T2DM, recruited into the concurrently
conducted population-based Tasmanian Study of Cognition
and Gait (TASCOG). TASCOG participants were randomly
identified from the electoral roll from the same postcodes as
those in CDOT. Absence of T2DM in our comparison group
was assessed using fasting plasma glucose <7.0mmol/L,
random plasma glucose <11.1mmol/L, and HbA1c < 6.5%
(48mmol/mol) in those without a history of T2DM. Exclu-
sion criteria were identical to the CDOT study. It must be
noted that retinal vascular measurements were introduced
into CDOT some months after commencement, resulting in
a smaller overall sample size compared with our previously
published paper describing brain atrophy in T2DM and its
link with cognition [2]. The Southern Tasmanian Health and
Medical Human Research Ethics Committee and theMonash
University Human Research Ethics Committee approved the
study and we obtained written informed consent.
2.2. Outcome Measurements
2.2.1. RetinalMeasurements. A45∘ digital disc centredCanon
CR-DGi nonmydriatic retinal camera was used to photo-
graph two fields per eye. The digitised retinal images were
graded by a single expert and processed using automated
algorithms at the National Heart & Lung Institute, Impe-
rial College, London, using well-established methods [21].
Color digital images (3072 × 2048 pixels) were converted to
monochrome by extraction of the green layer. Using a custom
written program in Matlab, vessel diameters were measured
using a Sliding Linear Regression Filter (SLRF) [22] which
achieves subpixel accuracy, and vessel length was measured
between bifurcations using automatic tracking. SLRF is based
on fitting a line by linear regression and progressivelymoving
this across the entire section of interest, thus significantly
decreasing noise. Measurements were made from ≥7 infor-
mative vessel segments and ≥5 bifurcations in both arterial
and venous vessels from each subject. An informative vessel
segment was defined to be either linking 2 clearly visible
bifurcations or else traversing a linear distance of ≥1.5 disc
diameters (the width of an average optic disc in photographic
images) from the optic disc boundary without bifurcating.
The analysis was performed on a sequence of complete trees
generally from a single eye, continuing on the second eye if
necessary to achieve the required number of vessel segments
and bifurcations. The following measures of retinal vessel
architecture were obtained: arteriolar and venular diameters
and length; length/diameter ratios (LDR) of arteriolar seg-
ments (correct for refractive errors affecting measurements);
arteriolar tortuosity; arteriolar bifurcation angles; arteriolar
optimality ratio; and optimality deviance. Tortuosity was
calculated as the ratio of arc length (𝑙
𝑎
) of the vessel segment
(measured by tracking) to the straight line length of the
segment (chord length, 𝑙
𝑐
). The relationship of arteriolar
diameters at bifurcations has been shown previously to relate
to endothelial function [23]. Optimality ratio is the ratio of
sum of “daughter” arteriolar diameters (𝑑
1
) divided by the
“parent” arteriolar diameter (𝑑
0
) corrected for asymmetry
[24]. Departure away from a theoretically predicted optimum
[25] is an indicator of endothelial dysfunction [21]. Accuracy
and reproducibility of our methods are high and have been
previously described with SLRF repeatability coefficient of
diameter measurement of 3.89 pixels [22].
Digital copies of the retinal photographs were also graded
by a single clinical expert trained in ophthalmology (B. C.
Amaratunge) for the presence/absence of features of any
clinical retinopathy blinded to diabetes status.These included
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the presence of optic disc disease, copper/silver wiring, gen-
eral arteriolar narrowing, focal arteriolar narrowing, arteri-
ovenous crossing abnormalities, microaneurysm, intraretinal
haemorrhage, nerve fibre haemorrhage, hard exudate, new
vessel formation, cotton wool spots, macular degeneration,
intraretinal microvascular abnormalities, and evidence of
photocoagulation therapy. Retinopathy previously described
as related to diabetes (diabetic retinopathy) was classified
based on the features used in the simplified version of the
Wisconsin grading system [26].
2.2.2. Brain MRI. MRI scans were obtained using a single
1.5 T General Electric scanner with the following sequences:
high-resolution T1-weighted spoiled gradient echo (SPGR)
(TR 35ms, TE 7ms, flip angle 35∘, field of view 24 cm,
120 contiguous slices, and isotropic voxel size 1mm3); T2-
weighted fast spin echo (TR 4300ms; TE 120ms; NEX 1;
turbo factor 48; voxel size 0.90 × 0.90 × 3mm); FLAIR (fluid
attenuated inversion recovery) (TR = 8802ms, TE = 130ms,
TI = 2200ms, and voxel size 0.50 × 0.50 × 3mm); gradient
echo (GRE, TR = 0.8ms; TE = 0.015; flip angle 30∘; voxel size
= 0.9 × 0.9 × 7mm).
2.2.3. Brain MRI Segmentation. 3D-T1 and gradient echo
(GRE) sequences were coregistered and a multispectral seg-
mentation process [27] was used to produce tissue probability
maps for gray matter and white matter using Statistical Para-
metric Mapping software version 8. Information from the
GRE sequence was used to enhance contrast of subcortical
structures prior to segmentation with SPM. Misclassifica-
tions of gray matter caused by white matter hyperintensities
(WMH) were corrected using coregistered WMHmaps pro-
duced using the automated procedure described previously
[28]. Tissue probability maps in native space were used
to compute tissue volume. Gray matter tissue maps were
transformed to standard space for voxelwise regression using
the nonlinear transformations estimated by the SPM tissue
classification analysis. Images were modulated to preserve
volume and smoothed with an isotropic Gaussian kernel,
full width at half maximum (FWHM) = 8mm. Voxel size of
images in standard space was 1.5mm3 voxels. A single expert
manually segmented both hippocampi using established
methods known to have high test-retest reliability in our
laboratory (ICC 0.97) [29]. Using the tissue maps generated
by these methods, total gray matter, white matter, and
hippocampal volumes were calculated with voxel counting
algorithms. WMH volumes were obtained by automated
segmentation as described previously [2]. A single trained
rater (C. Moran) determined the presence of MRI infarct and
microbleed with confirmation by consensus between 2 stroke
experts (T. G. Phan and V. Srikanth). Infarct was defined
as a hypointensity ≥3mm in diameter on 3D-T1-weighted
and FLAIR images with a surrounding hyperintense rim on
FLAIR [30]. Microbleeds were defined as small, rounded
hypointense lesions with clear margins, ranging from 2 to
10mm on GRE sequences. All measurements were blinded
to group, age, sex, and outcome measures.
2.2.4. Other Measurements. We used standardized question-
naires to record demographic and clinical information about
duration of T2DM, years of formal education, health and
medical history including vascular disease and risk factors,
smoking, medication use, and alcohol use (g/day). We mea-
sured weight, height, and waist and hip circumferences and
calculated Body Mass Index (BMI) as weight (kg)/height2
(m2); habitual physical activity by calculating mean number
of steps per day using a Yamax pedometer worn over a seven-
day period; mood using the 15-item Geriatric Depression
Scale (GDS) [31]; and blood pressure (BP) using an Omron
M4 sphygmomanometer in a sitting position as an average of
3 recordings from the right arm. Fasting plasma glucose was
recorded using a Roche Cobas 6000 analyser with hexokinase
determination and HbA1c using a Bio-Rad D10 analyser.
2.3. Data Analysis. Student’s 𝑡-tests, Mann-Whitney 𝑈 tests,
and Chi square tests were applied as appropriate to compare
mean scores and proportions of demographic and clinical
variables between people with and without T2DM.
2.3.1. Multivariable Regression. We first established the asso-
ciations of T2DM with individual MRI measures adjusting
in each regression for age and sex and additionally for total
intracranial volume (except in the case of MRI infarcts and
microbleeds). Linear regression was used for continuous
outcome variables (total gray, total white, and right and left
hippocampal volumes) and logistic regression for binary out-
comes (infarct or microbleed). For all above analyses, poten-
tial for confounding was examined for additional covariates
and adjustments made if addition of these terms changed the
coefficient for T2DM by >10%. Covariates considered were
hypertension (defined as mean BP > 140/90mmHg or previ-
ous diagnosis), use of blood pressure lowering medications,
hyperlipidaemia (yes/no), alcohol use (g/day), HbA1c, ever
smoked (yes/no), mean steps per day, ischemic heart disease,
stroke, BMI, and waist-hip ratio.
We then examined the relationship between T2DM
with the individual retinal measurements, before and after
adjusting for age and sex and vascular risk factors. We also
performed sensitivity analyses to examine whether measures
of T2DM severity (HbA1c and duration of T2DM) or the
use of blood pressure lowering medications altered the
relationship between T2DM and the retinal measures. To
examine whether retinal measures mediated the associations
detected between T2DM and brain volume, we entered
any retinal measure associated with T2DM into the model
relating T2DM to brain volume measures adjusting for age,
sex, and total intracranial volume. If the introduction of the
retinal measure substantially attenuated the 𝛽 coefficient for
T2DM and the coefficient of the retinal measure remained
unchanged from its unadjusted value without T2DM in
the model, it was considered a potential mediator. We also
examined for two-way interactions between T2DM and
retinal measures using a test of significance of product terms.
We applied standard regression diagnostics to assess the
adequacy of models. Statistical analyses were carried out
using STATA version 11.1 (StataCorp LP, College Station, TX).
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Table 1: Sample characteristics.
T2DM
Mean (SD) or 𝑛 (%)
𝑛 = 270
No T2DM
Mean (SD) or 𝑛 (%)
𝑛 = 181
p value
Age (years) 67.3 (6.7) 72.9 (6.7) <0.001
Male sex 159 (59) 97 (54) 0.27
Formal education (years) 11.2 (3.6) 11.0 (3.9) 0.61
Systolic blood pressure (SBP) (mmHg) 135 (19) 137 (19) 0.23
Diastolic blood pressure (DBP) (mmHg) 76 (10) 78 (11) 0.01
Self-reported history of hypertension or
mean SBP >140 or mean DBP >90mmHg 223 (83) 123 (68) <0.001
Use of blood pressure lowering
medications 190 (70) 85 (47) <0.001
Ischemic heart disease 57 (21) 27 (15) 0.01
TIA or stroke 22 (8) 9 (5) 0.19
Hyperlipidemia 127 (47) 10 (6) <0.001
Statin use 163 (60) 45 (25) 0.005
Ever smoked 144 (53) 89 (49) 0.36
Alcohol intake (g/day)∗ 12 (17) 17 (20) 0.001
BMI (kg/m2) 30.7 (5.1) 27.6 (4.3) <0.001
Waist-hip ratio 0.96 (0.09) 0.90 (0.09) <0.001
Median steps per day∗ (IQR) 5584 (3856–8461) 6328 (4471–8362) 0.21
GDS score∗ 2.4 (2.6) 1.5 (1.6) 0.001
Gray matter volume (mL) 661.1 (64.4) 656.4 (63.7) 0.47
White matter volume (mL) 499.8 (53.2) 493.5 (49.3) 0.23
White matter hyperintensity volume
(mL) 9.80 (6.3) 10.6 (7.1) 0.25
MRI infarct (presence) 54 (19) 22 (12) 0.03
MRI microbleed (presence) 9 (3) 12 (6) 0.79
Fasting blood glucose (mmol/L) 7.7 (2.1) 5.3 (0.6) <0.001
HbA1c (%) 7.1 (1.2) 5.6 (0.3) <0.001
Age at diabetes diagnosis† 57.6 (10.9) NA
Median duration of T2DM (years)† (IQR) 6 (4–11) NA
Insulin use† 53 (20) NA
T2DM:Type 2DiabetesMellitus; TIA: Transient IschemicAttack; BMI: BodyMass Index; GDS:GeriatricDepression Scale;MRI:Magnetic Resonance Imaging;
SD: Standard Deviation; NA: not applicable; IQR: interquartile range; ∗Mann-Whitney 𝑈 test; †in those with T2DM.
Voxelwise regression was performed using SPM to exam-
ine relationships of optimality ratio and retinal vessel diame-
ter with gray matter. Models were adjusted for total intracra-
nial volume and tested with and without adjustment for age
and sex. 𝑝 values were corrected for multiple comparisons
using familywise error rate of 0.05.
3. Results
Retinal photographs and MRI scans were available for 451
people, 270 with T2DM (mean age 67.3 years, SD 6.7), and
181 (mean age 72.9 years, SD 6.7) without T2DM. Sample
characteristics and comparisons between those with and
without T2DM are presented in Table 1. Those with T2DM
reported median disease duration of 6 years (interquartile
range 4–11 years), and 53 participants used insulin.Thosewith
T2DM had greater fasting blood glucose and HbA1c levels,
higher BMI and waist-hip ratio, and greater GDS score, were
more likely to report a history of ischemic heart disease,
hypertension, and hyperlipidaemia, and receive treatment
with blood pressure lowering drugs and statins (all 𝑝 < 0.05).
Retinal photographs could not be graded accurately in 15
people (10 with T2DM; 5 without T2DM) because of poor
image quality. Those with nongradable retinal photographs
were similar to those with gradable retinal photographs
in age, sex, mean fasting blood glucose and HbA1c levels,
BMI waist-hip ratio, GDS score, history of hypertension and
hyperlipidaemia, and treatment with blood pressure lowering
drugs and statins (data not shown). Compared with the sam-
ple described in our previously published report (𝑛 = 715)
[2], the sample in this retinal substudy was smaller; partic-
ipants were more likely to be on blood pressure reducing
Journal of Diabetes Research 5
Table 2: Association between Type 2 Diabetes Mellitus and retinal measurements∗.
Retinal variable Model 1
𝛽 (95% CI)
Model 2
𝛽 (95% CI)
Model 3
𝛽 (95% CI)
Arteriolar measures
Length, pixels 14.38 (−36.27 to 65.04) 13.01 (−42.00 to 68.01) 31.15 (−37.76 to 94.06)
Diameter, pixels 0.48 (0.05 to 0.91)† 0.34 (−0.13 to 0.80) 0.01 (−0.52 to 0.54)
Length/diameter ratio 0.08 (−2.11 to 2.26) 0.12 (−2.24 to 2.49) 1.24 (−1.46 to 3.95)
Simple tortuosity 0.007 (−0.001 to 0.02) 0.006 (−0.003 to 0.01) 0.006 (−0.003 to 0.02)
Internal angle (∘) 2.89 (−0.34 to 6.12) 2.83 (−0.66 to 6.33) 2.63 (−1.50 to 6.76)
Optimality ratio 0.01 (0.001 to 0.02)† 0.01 (−0.01 to 0.02) 0.004 (−0.01 to 0.02)
Venular measures
Length, pixels 3.87 (−31.40 to 39.14) 21.30 (−16.43 to 50.02) 8.30 (−35.99 to 52.59)
Diameter, pixels 0.08 (−0.61 to 0.77) −0.21 (−0.95 to 0.54) −0.45 (−1.32 to 0.43)
Length/diameter ratio 0.18 (−1.12 to 1.47) 0.95 (−0.44 to 2.33) 0.65 (−0.98 to 2.27)
Simple tortuosity 0.001 (−0.001 to 0.003) 0.002 (−0.001 to 0.004) 0.001 (−0.002 to 0.004)
Retinopathy
Any retinopathy (odds ratio) 1.00 (0.68 to 1.47) 1.47 (0.96 to 2.26) 1.41 (0.85 to 2.32)
∗Including nonsymmetrical second-order vessels for all bifurcations.
Model 1 unadjusted.
Model 2 adjusted for age and sex.
Model 3 adjusted for age, sex, and vascular risk factors (history of smoking, hypertension, systolic and diastolic blood pressure, BMI and history of stroke,
ischemic heart disease, and hyperlipidaemia).
†
𝑝 value < 0.05.
agents than those in the original sample (43% versus 61%,
resp.) but were not different with respect to age, sex, and
history of vascular risk factors (data not shown).
The comparisons of raw scores of retinal vascular mea-
sures are presented in Supplementary Tables 1 and 2 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2016/6328953. The associations of T2DM with retinal
measures are displayed in Table 2, first unadjusted, and
followed by additional adjustment for age and sex and further
for other covariates as required. Although T2DMwas associ-
ated with larger arteriolar diameter (𝑝 = 0.03) and optimality
ratio (𝑝 = 0.04) in univariable regression, these associations
were attenuated by further adjustment. T2DM was not asso-
ciatedwith any othermeasure of retinal vascular architecture.
Among those with T2DM, there was no association between
HbA1c or duration of T2DM and any of the retinal mea-
surements. With respect to features of clinical retinopathy,
a greater proportion of those with T2DM had copper/silver
wiring, generalized and focal narrowing, arteriovenous cross-
ing abnormalities, presence of microaneurysm, intraretinal
haemorrhage, hard exudates, and macular degeneration (all
𝑝 < 0.05). Overall there were no differences between groups
in the proportions of people with the presence of retinopathy
from any cause, but a significantly greater proportion with
diabetic retinopathy in the T2DM group (12% versus 4%;
𝑝 = 0.003) (Supplementary Table 2).
In the overall sample, only greater optimality ratio was
associated with lower gray matter volume (mL) (𝛽 = −22.15
95% CI −41.69 to −2.61; 𝑝 = 0.03) when adjusted for age, sex,
and total intracranial volume. Adjusting for vascular risk fac-
tors only slightly weakened this rendering it not statistically
significant (𝛽 = −19.13 95% CI −38.85 to 0.59; 𝑝 = 0.06).
Greater optimality ratio was also associated with a decreased
risk of infarcts (𝛽 = −4.97 95% CI −9.62 to −0.33; 𝑝 = 0.04).
Adjusting for vascular risk factors weakened this association
rendering it not statistically significant (𝛽 = −4.44 95% CI
−9.41 to 0.53; 𝑝 = 0.08). No associations were found between
any measure of retinal architecture and MRI brain volumes.
These associations did not differ in magnitude between
those with and without T2DM, and there were no statistical
interactions (Supplementary Table 3). Specifically, there were
no associations between the presence of diabetic retinopathy
and MRI measures (Supplementary Table 3). Voxelwise
regression also did not reveal associations of optimality ratio
or arteriolar diameter with gray matter. Table 3 shows the
effect of adding arteriolar diameter and optimality ratio to
regressionmodels of T2DMwith brainMRImeasures. Intro-
duction of these two measures did not meaningfully change
the association between T2DM and gray matter volume
and other MRI measures in fully adjusted models. All the
above described associations were not meaningfully different
in those taking blood pressure lowering medications from
those not taking blood pressure lowering medications.
4. Discussion
We examined the role of retinal vascular measures and
clinical retinopathy in mediating the association between
T2DM and MRI imaging biomarkers of brain disease. We
found that T2DM was associated with increased retinal
arteriolar diameter and optimality ratio and, as expected,
with several measures of clinical retinopathy. Only greater
retinal arteriolar optimality ratio was associated with lower
gray matter volume. The association between T2DM and
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Table 3: Association between T2DM and MRI measures.
Model 1
(T2DM)
Model 2
(𝛽 of T2DM)
Model 3
(𝛽 of T2DM)
Gray matter volume (mL) −3.60 (−6.28 to −0.93)∗ −3.70 (−6.39 to −1.01)∗ −3.68 (−6.36 to −1.01)∗
Right hippocampal volume (mL) 0.07 (−0.006 to 0.15) 0.07 (−0.005 to 0.15) 0.07 (−0.005 to 0.15)
Left hippocampal volume (mL) 0.02 (−0.05 to 0.10) 0.02 (−0.05 to 0.10) 0.02 (−0.05 to 0.10)
Total hippocampal volume (mL) 0.08 (−0.05 to 0.22) 0.08 (−0.05 to 0.22) 0.08 (−0.05 to 0.22)
White matter volume (mL) 0.15 (−2.54 to 2.84) 0.24 (−2.47 to 2.94) 0.23 (−2.48 to 2.93)
White matter hyperintensity
volume (mL) −0.06 (−1.46 to 1.34) −0.06 (−1.47 to 1.36) −0.05 (−1.47 to 1.36)
Infarct present (odds ratio) 2.31 (1.24 to 4.27)∗ 2.47 (1.32 to 4.63)∗ 2.55 (1.35 to 4.80)∗
Microbleed present (odds ratio) 0.47 (0.17 to 1.29) 0.50 (0.18 to 1.40) 0.50 (0.18 to 1.41)
T2DM: Type 2 Diabetes Mellitus; MRI: Magnetic Resonance Imaging.
Model 1, adjusted for age, sex, and intracranial volume.
Model 2 𝛽 of T2DM when adjusted for arteriolar diameter, age, sex, and intracranial volume.
Model 3 𝛽 of T2DM when adjusted for arteriolar diameter, optimality ratio, age, sex, and intracranial volume.
∗
𝑝 value < 0.01.
lower gray matter volume appeared to be independent of
retinal vascular architecture and clinical retinopathy.
A number of studies have examined the association
between retinal markers and brain imaging markers of
cerebrovascular disease and neurodegeneration in older
people [17, 32–35]. Some investigators have examined the
relationship between retinal measures and cognitive func-
tion [15, 36], and one group has reported a cross-sectional
association of retinopathy with lower gray matter volume
in those with T2DM [37]. However, none have specifically
examined whether retinal measures may mediate or modify
the association between T2DM and brain volume by com-
paring those with and without T2DM. The relatively high
prevalence of “any retinopathy” in our control group reflects
the blinded rating of retinopathy. Although the prevalence of
any retinopathy was similar between groups, the prevalence
of diabetic retinopathy in our study (12%) was appropriately
greater in those with T2DM and similar to that seen in
other large community based studies of T2DM (∼10%) [18,
38]. Measures of retinal vessel architecture have also been
reported to be abnormal in T2DM probably as a result of
chronic inflammation or endothelial dysfunction [39–41].
Consistent with some previous studies we found T2DM to be
associated with larger retinal arteriolar diameter [19, 42] and
for the first time demonstrate a relationship with optimality
ratio, but not other measures of retinal architecture. It is pos-
sible that the lack of associations of T2DM with other retinal
vascular measures could be explained by the close-to-target
HbA1c (mean HbA1c 7.1%) and the high use of blood pressure
lowering and cholesterol lowering medications in those with
T2DM. However, controlling for HbA1c, duration of diabetes,
or the use of these medications did not significantly change
the observed relationships. An alternative explanation is
that retinal photography may not be sufficiently sensitive to
measure disease at the level of truemicrovessels (blood retinal
barrier) which is more likely to reflect the structure of the
blood brain barrier or neurovascular unit. Dysfunction at the
level of the neurovascular unit may still be a contributing
factor for neuronal loss. Our results are further supported
by a recent study in which Type 1 Diabetes Mellitus (T1DM)
was associated with lower subcortical volume compared with
those without T1DM and this association was independent of
the presence of proliferative retinopathy [43]. Further work
from the same group reported that those with T1DM and
proliferative retinopathy had more cerebral microbleeds and
skin capillary pathology, suggesting a generalized microan-
giopathy [44]. Those with T1DM often have greater disease
duration and exposure to greater levels of hyperglycaemia
than those with T2DM and therefore it is possible that
duration and severity of T2DM are stronger predictors of
vascular and cerebral complications than the diagnosis alone.
The mechanisms through which T2DM may contribute
to lower gray matter volume may also include pathways that
do not involve changes to microvascular architecture. T2DM
is associated with chronic inflammation, oxidative stress [39–
41], and, in a recent study, increased cerebrospinal levels of the
protein tau [45], all of which can contribute to neuronal loss.
Studies linking the pre-T2DM risk factors of obesity, insulin
resistance, and the metabolic syndrome with brain atrophy
further support the role of inflammation and oxidative stress
as potential mediators of T2DM-related brain atrophy [46–
48].
Strengths of our study include large sample size, robust
phenotyping of T2DM, the use of fully automated brain seg-
mentation, comprehensive measures of retinal vessel archi-
tecture and retinopathy, measurements blinded to diabetes
status, and careful regressionmodelling to examine formedi-
ation and effect modification. Importantly, our comparison
sample was drawn from the same source population as
those with T2DM. Our study has limitations. Participants on
averagewere not very old and hence less likely to demonstrate
substantial variation in MRI or retinal biomarkers. The sam-
ple in this study was smaller (𝑛 = 451) than that described in
our previously published work (𝑛 = 713) [2]. This is because
retinal photography was introduced as a measurement at a
later stage of recruitment. Although recruitment strategies
did not vary before and after introduction of retinal mea-
sures, it is possible that some selection bias may have been
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introduced that may have led to weaker associations being
detected between T2DM and both retinal andMRI measure-
ments. Although the two samples did not differ with respect
to age, sex, and other vascular risk factors, the use of blood
pressure loweringmedicationwas higher in this study sample
and this may have protected against more severe retinopathy
or brain changes. However, the sample in this study was
similar to our previously published work with regard to age,
sex, and vascular risk factors. It is also possible that the retinal
photographs of those with the most severe retinal changes
may have been excluded due to poor quality, but those
excluded did not appreciably differ from those included on
other important characteristics. However, it remains possible
that a greater load of retinal vascular disease may explain
some of the T2DM-brain volume relationship. Given the
cross-sectional design of our study, the results need to be
confirmed in longitudinal analyses before firm conclusions
can be drawn about the lack of a role for retinal vascular
disease in explaining theT2DM-brain volume link.We exam-
ined a large number of associations between retinal measures
(eleven) and structural brain measures (six). Multiple com-
parison testing increases the chance of finding an association
where none exists and cannot be excluded as an explanation
for the associations we found between optimality ratio and
GMV.
5. Conclusions
The associations between T2DM and brain volume appeared
independent of retinal measures. Longitudinal confirmation
of these findingswould be important in establishing pathways
linking T2DM and dementia.
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